6-Mercaptopurine

6-Mercaptopurine (also known as 6-MP) is a chemotherapy medication primarily used to treat leukemia. It is a purine analogue that interferes with DNA and RNA synthesis, thereby preventing cell division and growth.

History

6-Mercaptopurine was first synthesized and developed by Gertrude Elion and George Hitchings, who were awarded the Nobel Prize in Physiology or Medicine in 1988 for their work in the field of medicine and pharmacology.

Medical Uses

6-Mercaptopurine is used in the treatment of acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and non-Hodgkin's lymphoma. It is also used in the management of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, when other treatments have not been effective.

Mechanism of Action

6-Mercaptopurine works by inhibiting the synthesis of purine molecules, which are essential for DNA replication. This inhibition prevents the growth and multiplication of rapidly dividing cells, such as cancer cells.

Side Effects

Common side effects of 6-Mercaptopurine include nausea, vomiting, loss of appetite, and diarrhea. More serious side effects can include bone marrow suppression, liver toxicity, and an increased risk of infection due to a weakened immune system.

Interactions

6-Mercaptopurine can interact with several other medications, including allopurinol, warfarin, and certain antibiotics. It is important for patients to inform their healthcare provider of all medications they are currently taking to avoid potential drug interactions.

See Also

• Chemotherapy
• Leukemia
• Inflammatory bowel disease
• Gertrude Elion
• George Hitchings